AMCP Formulary Dossier Guidelines For Companion Dx To Be Final By 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
An addendum to existing standards for drug dossiers aims to provide more guidance on the types of evidence that payers could request on the use of companion diagnostics for drugs. It also clarifies for diagnostic and drug manufacturers on what evidence would be reported by which company.